Marinus Pharmaceuticals (NASDAQ:MRNS) Upgraded by EF Hutton Acquisition Co. I to “Strong-Buy”

EF Hutton Acquisition Co. I upgraded shares of Marinus Pharmaceuticals (NASDAQ:MRNS) to a strong-buy rating in a research report report published on Monday, Zacks.com reports.

Several other research analysts have also recently weighed in on MRNS. Truist Financial restated a buy rating and issued a $10.00 price objective on shares of Marinus Pharmaceuticals in a research report on Tuesday, June 18th. StockNews.com downgraded Marinus Pharmaceuticals from a hold rating to a sell rating in a research report on Thursday, September 26th. HC Wainwright reiterated a buy rating and issued a $11.00 price objective on shares of Marinus Pharmaceuticals in a report on Wednesday, August 14th. JMP Securities reiterated a market outperform rating and set a $10.00 price objective on shares of Marinus Pharmaceuticals in a research report on Monday, September 23rd. Finally, Cantor Fitzgerald restated an overweight rating and issued a $13.00 target price on shares of Marinus Pharmaceuticals in a research report on Tuesday, September 24th. One analyst has rated the stock with a sell rating, three have given a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of Moderate Buy and an average price target of $8.83.

Marinus Pharmaceuticals Stock Down 5.1 %

MRNS opened at $1.67 on Monday. The firm has a market capitalization of $91.74 million, a P/E ratio of -0.63 and a beta of 1.13. Marinus Pharmaceuticals has a one year low of $1.05 and a one year high of $11.26. The company has a fifty day moving average price of $1.42 and a 200-day moving average price of $2.42. The company has a debt-to-equity ratio of 5.68, a current ratio of 2.28 and a quick ratio of 2.15.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.01). The business had revenue of $8.06 million for the quarter, compared to analysts’ expectations of $9.05 million. Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 493.14%. During the same quarter in the previous year, the firm earned ($0.61) earnings per share. Equities research analysts expect that Marinus Pharmaceuticals will post -1.88 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Marinus Pharmaceuticals

A number of large investors have recently bought and sold shares of the stock. Hussman Strategic Advisors Inc. boosted its stake in shares of Marinus Pharmaceuticals by 14.3% during the second quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 10,500 shares during the period. AQR Capital Management LLC raised its holdings in Marinus Pharmaceuticals by 70.3% during the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 12,934 shares during the last quarter. Point72 DIFC Ltd purchased a new stake in Marinus Pharmaceuticals during the 2nd quarter valued at $28,000. SG Americas Securities LLC bought a new stake in Marinus Pharmaceuticals in the 2nd quarter worth $34,000. Finally, Jacobs Levy Equity Management Inc. bought a new stake in Marinus Pharmaceuticals in the 1st quarter worth $384,000. 98.80% of the stock is owned by hedge funds and other institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.